风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

美国批准Janssen的艾滋病毒药物Symtuza

2018-07-18 MedSci MedSci原创

JanssenSymtuza
关注

Janssen的Symtuza已被美国监管机构批准为第一个也是唯一一个完整的，基于darunavir的单片治疗方案，用于治疗成人HIV。根据Janssen的说法，单项治疗方案有能力提高依从性并减轻药物负担。它说："在为提高耐受性和便利性而设计的配方中，darunavir的耐药性已经被证明是有效的防护屏障。""作为临床医生，我们可能并不总是能够全面了解患者的健康状况或他们在做出治疗决策时产生耐药性的



Janssen的Symtuza已被美国监管机构批准为第一个也是唯一一个完整的，基于darunavir的单片治疗方案，用于治疗成人HIV。

根据Janssen的说法，单项治疗方案有能力提高依从性并减轻药物负担。它说："在为提高耐受性和便利性而设计的配方中，darunavir的耐药性已经被证明是有效的防护屏障。"

"作为临床医生，我们可能并不总是能够全面了解患者的健康状况或他们在做出治疗决策时产生耐药性的风险，"北卡罗来纳大学艾滋病研究中心医学教授兼临床核心主任Joseph Eron说。

"在关键的III期临床试验中，Symtuza成功治疗了那些开始治疗的患者，以及那些在抗逆转录病毒（ARV）治疗中被稳定抑制的患者--包括具有更复杂治疗史或先前病毒失败的患者 - 证明其作为各种患者的重要新治疗选择的潜力。

该批准是基于两项为期48周的III期研究的数据，这些研究评估了Symtuza与没有抗逆转录病毒史的成人（AMBER）和病毒学抑制成人（EMERALD）的对照方案的安全性和有效性。

两项试验的结果均显示Symtuza有效且耐受良好，高达95％达到或维持病毒抑制。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2019-02-15 venlin

    #艾滋病毒药物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-11-29 12498cf9m35(暂无昵称)

    #美国批准#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-22 1e1c07bdm01(暂无匿称)

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-21 1e1c07bdm01(暂无匿称)

    好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-20 zhang92564

    #Janssen#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-20 1e1c07bdm01(暂无匿称)

    好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-19 131****1460

    学习了受益匪浅

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-19 kafei

    学习了谢谢

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-19 liumin1987

    抗艾滋病病**物为艾滋病的治疗提供了选择

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1811118, encodeId=025c18111187f, content=<a href='/topic/show?id=fbba86818bb' target=_blank style='color:#2F92EE;'>#艾滋病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86818, encryptionId=fbba86818bb, topicName=艾滋病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Feb 15 09:47:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055044, encodeId=45e7205504483, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Nov 29 00:47:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333264, encodeId=0c8f33326406, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Jul 22 06:27:38 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333061, encodeId=24df33306126, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Jul 21 06:12:22 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Fri Jul 20 12:47:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332828, encodeId=120e3328285f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Jul 20 06:16:34 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332663, encodeId=54673326638f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jul 19 08:25:42 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332646, encodeId=333c332646df, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Jul 19 07:19:53 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332643, encodeId=c97d33264338, content=抗艾滋病病**物为艾滋病的治疗提供了选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Jul 19 07:18:14 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332627, encodeId=200a33262e48, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jul 19 06:45:44 CST 2018, time=2018-07-19, status=1, ipAttribution=)]
    2018-07-19 zb1235672

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Janssen购买了Legend的CART疗法

Janssen已经与Legend Biotech USA和Legend Biotech Ireland签署了一项全球协作和许可协议，开发，制造和销售实验性CART细胞疗法LCAR-B38M。目前，中国的监管机构正在对LCAR-B38M进行研究，该研究专门针对B细胞成熟抗原（BCMA），这是一种在骨髓瘤细胞中高表达的蛋白质，在美国临床研究的计划阶段正在进行多发性骨髓瘤的研究。根据协议条款，作为3.5

Janssen的Imbruvica最终被纳入NHS

Janssen的Imbruvica将被纳入NHS，用于某些患有套细胞淋巴瘤（MCL）患者的常规治疗，此前成本监管机构已经为该药发布了最后的绿灯。在最后的指导方针中，英国国家医疗服务体系批准Imbruvica（ibrutinib）用于治疗只有这一种选择的患者。该机构之前表示，它不能为整个MCL患者群推荐该药，因为它没有提供NHS的资金价值，但是在二级保健中，Imbruvica可以被认为处于"临终"阈

Janssen收购BeneVir Biopharm以推进免疫治疗方案

Janssen签署了一份最终协议，收购一家私人控股的生物制药公司BeneVir Biopharm，该公司专注于开发溶瘤性免疫疗法。BeneVir利用专有的T-Stealth溶瘤病毒平台来设计能够感染和破坏癌细胞的溶瘤病毒。"溶瘤病毒免疫治疗通过激发和增强抗肿瘤免疫应答在治疗实体瘤方面具有令人兴奋的潜力，" Janssen研发部全球肿瘤治疗领域负责人Peter Lebowitz说。"BeneVir独

Janssen启动了Crohn''s药物Tremfya的PhII / III期计划

Janssen启动了一项评估克罗恩病Tremfya的II / III期计划。GALAXY计划将包括一项II期研究（GALAXY 1），随后进行两项III期研究（GALAXI 2和GALAXI 3），预计将招募约2，000名患者。Tremfya（guselkumab）的安全性和有效性将在患有中度至重度活动形式的克罗恩病的患者中进行评估，克罗恩病是一种无法治愈的炎症性肠病。Tremfya是由Janss